{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:46:07Z","timestamp":1779313567347,"version":"3.51.4"},"reference-count":40,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:00:00Z","timestamp":1746316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Algorithms"],"abstract":"<jats:p>Bioequivalence assessment of highly variable drugs (HVDs) remains a significant challenge, as the application of scaled approaches requires replicate designs, complex statistical analyses, and varies between regulatory authorities (e.g., FDA and EMA). This study introduces the use of artificial intelligence, specifically Wasserstein Generative Adversarial Networks (WGANs), as a novel approach for bioequivalence studies of HVDs. Monte Carlo simulations were conducted to evaluate the performance of WGANs across various variability levels, population sizes, and data augmentation scales (2\u00d7 and 3\u00d7). The generated data were tested for bioequivalence acceptance using both EMA and FDA scaled approaches. The WGAN approach, even applied without scaling, consistently outperformed the scaled EMA\/FDA methods by effectively reducing the required sample size. Furthermore, the WGAN approach not only minimizes the sample size needed for bioequivalence studies of HVDs, but also eliminates the need for complex, costly, and time-consuming replicate designs that are prone to high dropout rates. This study demonstrates that using WGANs with 3\u00d7 data augmentation can achieve bioequivalence acceptance rates exceeding 89% across all FDA and EMA criteria, with 10 out of 18 scenarios reaching 100%, highlighting the WGAN method potential to transform the design and efficiency of bioequivalence studies. This is a foundational step in utilizing WGANs for the bioequivalence assessment of HVDs, highlighting that with clear regulatory criteria, a new era for bioequivalence evaluation can begin.<\/jats:p>","DOI":"10.3390\/a18050266","type":"journal-article","created":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T20:10:27Z","timestamp":1746389427000},"page":"266","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Generative Neural Networks for Addressing the Bioequivalence of Highly Variable Drugs"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0828-315X","authenticated-orcid":false,"given":"Anastasios","family":"Nikolopoulos","sequence":"first","affiliation":[{"name":"Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece"},{"name":"Institute of Applied and Computational Mathematics, Foundation for Research and Technology Hellas (FORTH), 70013 Heraklion, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0492-0712","authenticated-orcid":false,"given":"Vangelis D.","family":"Karalis","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece"},{"name":"Institute of Applied and Computational Mathematics, Foundation for Research and Technology Hellas (FORTH), 70013 Heraklion, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1208\/s12248-009-9142-z","article-title":"Bioequivalence; Its History, Practice, and Future","volume":"11","author":"Midha","year":"2009","journal-title":"AAPS J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/jppr2004343195","article-title":"Bioequivalence: How, Why, and What Does it Really Mean?","volume":"34","author":"Pearce","year":"2004","journal-title":"Pharm. Pract. Res."},{"key":"ref_3","unstructured":"European Medicines Agency (2010). Guideline on the Investigation of Bioequivalence, Committee for Medicinal Products for Human Use (CHMP). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf."},{"key":"ref_4","unstructured":"European Medicines Agency (2025). ICH Guideline M13A on Bioequivalence for Immediate-Release Solid Oral Dosage Forms\u2014Scientific Guideline, European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/ich-guideline-m13a-bioequivalence-immediate-release-solid-oral-dosage-forms-scientific-guideline."},{"key":"ref_5","unstructured":"U.S. Food and Drug Administration (2025, January 11). Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs\u2014General Considerations, Available online: https:\/\/www.fda.gov\/media\/88254\/download."},{"key":"ref_6","first-page":"485","article-title":"The Bioequivalence of Highly Variable Drugs and Drug Products","volume":"43","author":"Midha","year":"2005","journal-title":"Clin. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1007\/s11095-011-0651-y","article-title":"Bioequivalence of Highly Variable Drugs: A Comparison of the Newly Proposed Regulatory Approaches by FDA and EMA","volume":"29","author":"Karalis","year":"2011","journal-title":"Pharm. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11095-007-9434-x","article-title":"Bioequivalence Approaches for Highly Variable Drugs and Drug Products","volume":"25","author":"Haidar","year":"2007","journal-title":"Pharm. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/11318040-000000000-00000","article-title":"Evaluation of Bioequivalence for Highly Variable Drugs with Scaled Average Bioequivalence","volume":"48","author":"Tothfalusi","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Vora, L.K., Gholap, A.D., Jetha, K., Thakur, R.R.S., Solanki, H.K., and Chavda, V.P. (2023). Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15071916"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Karalis, V.D. (2024). A Vector Theory of Assessing Clinical Trials: An Application to Bioequivalence. J. Cardiovasc. Dev. Dis., 11.","DOI":"10.3390\/jcdd11070185"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.tips.2019.05.005","article-title":"Artificial Intelligence for Clinical Trial Design","volume":"40","author":"Harrer","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_13","first-page":"32","article-title":"The Future of Pharmacy: How AI Is Revolutionizing the Industry","volume":"1","author":"Khan","year":"2023","journal-title":"Intell. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/13696998.2023.2249758","article-title":"Applications of AI in Pharmacy Practice: A Look at Hospital and Community Settings","volume":"26","year":"2023","journal-title":"J. Med. Econ."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e52073","DOI":"10.2196\/52073","article-title":"Preliminary Evidence of the Use of Generative AI in Health Care Clinical Services: Systematic Narrative Review","volume":"12","author":"Yim","year":"2024","journal-title":"JMIR Med. Inform."},{"key":"ref_16","first-page":"1","article-title":"Transforming Clinical Trials: Harnessing the Power of Generative AI for Innovation and Efficiency","volume":"6","author":"Sehrawat","year":"2023","journal-title":"Trans. Recent Dev. Health Sect."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Papadopoulos, D., and Karalis, V.D. (2023). Variational Autoencoders for Data Augmentation in Clinical Studies. Appl. Sci., 13.","DOI":"10.3390\/app13158793"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e55957","DOI":"10.2196\/55957","article-title":"Toward Clinical Generative AI: Conceptual Framework","volume":"3","author":"Bragazzi","year":"2024","journal-title":"JMIR AI"},{"key":"ref_19","unstructured":"Fleurence, R., Bian, J., Wang, X., Xu, H., Dawoud, D., Higashi, M., and Chhatwal, J. Generative AI for Health Technology Assessment: Opportunities, Challenges, and Policy Considerations, arXiv."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Marchesi, R., Micheletti, N., Kuo, N.I., Barbieri, S., Jurman, G., and Osmani, V. (2023). Generative AI Mitigates Representation Bias and Improves Model Fairness Through Synthetic Health Data. medRxiv.","DOI":"10.1101\/2023.09.26.23296163"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"112223","DOI":"10.1016\/j.asoc.2024.112223","article-title":"Challenges and Opportunities of Generative Models on Tabular Data","volume":"166","author":"Wang","year":"2024","journal-title":"Appl. Soft Comput."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Nikolopoulos, A., and Karalis, V.D. (2024). Implementation of a Generative AI Algorithm for Virtually Increasing the Sample Size of Clinical Studies. Appl. Sci., 14.","DOI":"10.3390\/app14114570"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1145\/3422622","article-title":"Generative Adversarial Networks","volume":"63","author":"Goodfellow","year":"2020","journal-title":"Commun. ACM"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1145\/3446374","article-title":"Generative Adversarial Networks (GANs)","volume":"54","author":"Saxena","year":"2021","journal-title":"ACM Comput. Surv."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Solanki, A., and Naved, M. (2023). GANs for Data Augmentation in Healthcare, Springer International Publishing.","DOI":"10.1007\/978-3-031-43205-7"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10347","DOI":"10.1007\/s11042-024-19361-y","article-title":"Understanding GANs: Fundamentals, Variants, Training Challenges, Applications, and Open Problems","volume":"84","author":"Ahmad","year":"2024","journal-title":"Multimed. Tools Appl."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Vlachou, M., and Karalis, V. (2021). An in Vitro\u2013in Vivo Simulation Approach for the Prediction of Bioequivalence. Materials, 14.","DOI":"10.3390\/ma14030555"},{"key":"ref_28","first-page":"30","article-title":"Bioequivalence Study of Two Formulations of Simvastatin 20 Mg Tablet in Healthy Filipino Participants under Fasting Conditions: A Randomized, Open-Label, Two-Way Crossover Study","volume":"58","author":"Alvero","year":"2023","journal-title":"Acta Medica Philipp."},{"key":"ref_29","first-page":"25","article-title":"The Rise of Artificial Intelligence in Healthcare Applications","volume":"2020","author":"Bohr","year":"2020","journal-title":"Artif. Intell. Healthc."},{"key":"ref_30","first-page":"295","article-title":"AI in Healthcare","volume":"284","author":"Koski","year":"2021","journal-title":"Stud. Health Technol. Inform."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Lee, D., and Yoon, S.N. (2021). Application of Artificial Intelligence-Based Technologies in the Healthcare Industry: Opportunities and Challenges. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18010271"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Shaheen, M.Y. (2021). Applications of Artificial Intelligence (AI) in Healthcare: A Review. Sci. Prepr.","DOI":"10.14293\/S2199-1006.1.SOR-.PPVRY8K.v1"},{"key":"ref_33","first-page":"1","article-title":"AI Applications in Healthcare: A Comprehensive Review of Advancements and Challenges","volume":"6","author":"Kasula","year":"2023","journal-title":"Int. J. Inf. Syst. Comput. Sci."},{"key":"ref_34","first-page":"79","article-title":"Regulating Generative AI: A Pathway to Ethical and Responsible Implementation","volume":"12","author":"Luckett","year":"2023","journal-title":"Int. J. Comput. Intell."},{"key":"ref_35","first-page":"61","article-title":"Generative Artificial Intelligence: Risks of Data Acquisition, Regulatory Deficiencies, and Suggestions for Countermeasures\u2014From the Inspiration of European Union Legislation","volume":"6","author":"Xinru","year":"2024","journal-title":"Int. J. Financ. Stud."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Luk, C.Y., Chung, H.L., Yim, W.K., and Leung, C.W. (2025, April 23). Regulating Generative AI: Ethical Considerations and Explainability Benchmarks. Available online: https:\/\/osf.io\/preprints\/osf\/h74gw_v1.","DOI":"10.31219\/osf.io\/h74gw"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41746-023-00873-0","article-title":"The Imperative for Regulatory Oversight of Large Language Models (or Generative AI) in Healthcare","volume":"6","author":"Topol","year":"2023","journal-title":"NPJ Digit. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Papadopoulos, D., Karali, G., and Karalis, V.D. (2024). Bioequivalence Studies of Highly Variable Drugs: An Old Problem Addressed by Artificial Neural Networks. Appl. Sci., 14.","DOI":"10.3390\/app14125279"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Wang, W., and Pai, T.-W. (2023). Enhancing Small Tabular Clinical Trial Dataset through Hybrid Data Augmentation: Combining SMOTE and WCGAN-GP. Data, 8.","DOI":"10.3390\/data8090135"},{"key":"ref_40","unstructured":"Trabucco, B., Doherty, K., Gurinas, M., and Salakhutdinov, R. (2023). Effective Data Augmentation with Diffusion Models. arXiv."}],"container-title":["Algorithms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4893\/18\/5\/266\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:26:59Z","timestamp":1760030819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4893\/18\/5\/266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,4]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["a18050266"],"URL":"https:\/\/doi.org\/10.3390\/a18050266","relation":{},"ISSN":["1999-4893"],"issn-type":[{"value":"1999-4893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,4]]}}}